Oric Pharmaceuticals, Inc.

The momentum for this stock is not very good. Oric Pharmaceuticals, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Oric Pharmaceuticals, Inc..

News

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...\n more…

Oric Pharmaceuticals initiated with bullish view at Stifel, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Globe Newswire SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...\n more…

ORIC Crosses Above Key Moving Average Level

Market News Video In trading on Monday, shares of Oric Pharmaceuticals Inc (ORIC) crossed above their 200 day moving average of 9.82, changing hands as high as 9.94 per share. Oric Pharmaceuticals Inc...\n more…

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Simply Wall St Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...\n more…

ORIC Stock Earnings: ORIC Pharmaceuticals Misses EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nORIC stock results show that ORIC Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…